UK advisory body releases report on impact of DNA patents on diagnostics innovation
This article was originally published in SRA
Executive Summary
A report by the UK Human Genetics Commission on the impact of DNA patents on diagnostics innovation highlights the tension between rising regulatory hurdles - in the form of demands for greater evidence of clinical utility - and the lack of incentive to make the necessary investment in clinical research1,2.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.